1. Home
  2. REFR vs ICUCW Comparison

REFR vs ICUCW Comparison

Compare REFR & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REFR
  • ICUCW
  • Stock Information
  • Founded
  • REFR 1965
  • ICUCW N/A
  • Country
  • REFR United States
  • ICUCW United States
  • Employees
  • REFR N/A
  • ICUCW 19
  • Industry
  • REFR Multi-Sector Companies
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • REFR Miscellaneous
  • ICUCW Health Care
  • Exchange
  • REFR Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • REFR N/A
  • ICUCW N/A
  • IPO Year
  • REFR N/A
  • ICUCW 2021
  • Fundamental
  • Price
  • REFR $1.72
  • ICUCW $0.03
  • Analyst Decision
  • REFR
  • ICUCW
  • Analyst Count
  • REFR 0
  • ICUCW 0
  • Target Price
  • REFR N/A
  • ICUCW N/A
  • AVG Volume (30 Days)
  • REFR 31.1K
  • ICUCW N/A
  • Earning Date
  • REFR 07-31-2025
  • ICUCW N/A
  • Dividend Yield
  • REFR N/A
  • ICUCW N/A
  • EPS Growth
  • REFR N/A
  • ICUCW N/A
  • EPS
  • REFR N/A
  • ICUCW N/A
  • Revenue
  • REFR $1,581,929.00
  • ICUCW N/A
  • Revenue This Year
  • REFR N/A
  • ICUCW N/A
  • Revenue Next Year
  • REFR N/A
  • ICUCW N/A
  • P/E Ratio
  • REFR N/A
  • ICUCW N/A
  • Revenue Growth
  • REFR 62.28
  • ICUCW N/A
  • 52 Week Low
  • REFR $0.93
  • ICUCW N/A
  • 52 Week High
  • REFR $2.39
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • REFR 61.45
  • ICUCW N/A
  • Support Level
  • REFR $1.56
  • ICUCW N/A
  • Resistance Level
  • REFR $1.95
  • ICUCW N/A
  • Average True Range (ATR)
  • REFR 0.12
  • ICUCW 0.00
  • MACD
  • REFR 0.02
  • ICUCW 0.00
  • Stochastic Oscillator
  • REFR 74.47
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: